scholarly journals Estimating the impact of depressive symptoms on osteoarthritis pain using marginal structural models: Data from the Osteoarthritis Initiative

2016 ◽  
Vol 24 ◽  
pp. S199
Author(s):  
A.M. Rathbun ◽  
E. Stuart ◽  
M. Shardell ◽  
M. Yau ◽  
M. Hochberg
Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 3365-3365
Author(s):  
Matthieu Resche-Rigon ◽  
Marie Robin ◽  
Regis Peffault de Latour ◽  
Sylvie Chevret ◽  
Gerard P Socie

Abstract Abstract 3365 Poster Board III-253 Introduction: Although allogeneic SCT with RIC has now gained wide acceptance, its eventual benefit again non-transplant approach is largely unknown (outside the setting of large randomized trials). When evaluating the impact on survival of reduced intensity conditioning in malignant hematological diseases, standard estimations based on Cox regression from observational databases could be biased because they ignore covariates that confound treatment decision. In this setting, we applied and compared two different statistical methods that were developed to control for confounding in estimating exposure (or treatment) effect from epidemiological studies. Patients and Methods: The statistical challenge was that allograft tended to be given when a patient was in advanced phase of his/her hematological malignancy, so that treatment was confounded by performance indicators, which in turn lie on the causal pathway between treatment and outcome. Thus, comparison of outcome first used propensity score (PS) analyses that attempt to create a comparison group of non-treated patients that closely resembles the group of treated patients by matching for the likelihood that a given patient has received the treatment. Then, we used marginal structural models (MSMs) that consist in creating, by using inverse probability of treatment weights, a pseudo-population in which the probability of treatment does no longer depend on covariates, and the effect of treatment on outcome is the same as in the original population. Result: Reduced intensity conditioning allograft was performed in 82 patients with chemotherapy-sensitive patients relapsing after autologous transplantation. Patients with myeloma (MM, 23 pts), follicular lymphoma (FL, 28 pts) or Hodgkin disease (HD, 31 pts), were compared to 276 patients who relapsed after autologous transplantation but did not underwent allogeneic stem cell transplantation (142 MM, 115 FL and 19 HD). From original datasets, 21 (91%) matched pairs could be constituted from MM patients, as compared to 19 (68%) of the FL patients, down to 15 (48%) of the HD patients. Based on these PS-matched samples, a significant benefit of reduced intensity conditioning as compared with non allografted patients was observed in MM, with estimated hazard ratio (HR) of death at 0.34 (95% confidence interval, CI: 0.14-0.88), as well as in FL (HR= 0.78, 95%CI: 0.27;2.30) and in HD (HR= 0.24; 95%CI: 0.09-0.62). MSM-based analyses that applied to the reweighted populations confirmed these trends towards survival benefits in FL, though partially erased in MM and HD. Conclusions: We reported the application of marginal structural models, a new class of causal models to estimate the effect of nonrandomized treatments as an alternative to PS based approaches in small samples. We expect that an increasing number of physicians involved in clinical cohorts become familiar with these novel and appealing quantitative methods when assessing innovative treatment effects. Disclosures: No relevant conflicts of interest to declare.


2015 ◽  
pp. kwv152
Author(s):  
Nassim Mojaverian ◽  
Erica E. M. Moodie ◽  
Alex Bliu ◽  
Marina B. Klein

2018 ◽  
Vol 13 ◽  
Author(s):  
Beth Hahn ◽  
Ami R. Buikema ◽  
Lee Brekke ◽  
Amy Anderson ◽  
Eleena Koep ◽  
...  

Background: Chronic obstructive pulmonary disease (COPD) is associated with high clinical and economic burden. Optimal pharmacological therapy for COPD aims to reduce symptoms and the frequency and severity of exacerbations. Umeclidinium/vilanterol (UMEC/VI) is an approved combination therapy for once-daily maintenance treatment of patients with COPD. This study evaluated the impact of delaying UMEC/VI initiation on medical costs and exacerbation risk. Methods: A retrospective analysis of patients with COPD who initiated UMEC/VI between 4/28/2014 and 7/31/2016 was conducted using the Optum Research Database. The index date was the first COPD visit after UMEC/VI available on US formulary (Commercial 4/28/2014; Medicare Advantage 1/1/2015). Patients were followed for 12 months post-index, and categorized into 12 cohorts corresponding to month (30-day period) of UMEC/VI initiation (i.e. Months 1–12) post-index. The outcomes studied during the follow up period included COPD-related and all-cause medical costs, and risk of COPD exacerbations. Marginal structural models (MSM) were used to control for time-varying confounding due to changes in treatment and severity during follow up. Results: 2,200 patients initiating UMEC/VI were included in the study sample. Patients’ average age was 69.3 years, 49.9% were female and 69.7% were Medicare insured. Following MSM analysis, 12-month adjusted COPD-related medical costs increased by 2.9% (95% confidence interval [CI]: 0.1–5.9%; p = 0.044) for each monthly delay in UMEC/VI initiation, with a 37.4% higher adjusted cost for patients initiating UMEC/VI in Month 12 versus Month 1 ($13,087 vs. $9524). The 12-month adjusted all-cause medical costs increased by 2.8% (95% CI: 0.6–5.2%; p = 0.013) for each monthly delay, with a 36.1% higher adjusted cost for patients initiating UMEC/VI at Month 12 versus Month 1 ($22,766 vs. $16,727). The monthly risk of severe exacerbation was significantly higher in patients who had not yet initiated UMEC/VI than those who had (hazard ratio: 1.74; 95% CI: 1.35–2.23; p < 0.001). Conclusions: Prompt use of UMEC/VI following a physician visit for COPD appears to result in economic and clinical benefits, with reductions in medical costs and exacerbation risk. Additional research is warranted to assess the benefits of initiating UMEC/VI as a first-line therapy compared with escalation to UMEC/VI from monotherapies.


Sign in / Sign up

Export Citation Format

Share Document